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To the Editor: I read with great interest the recent paper
by Kutner et al.1 on the effect of Hurricane Katrina and the
mortality of dialysis patients. To be sure, as noted by Kutner
et al., ‘each disaster may present a different set of circum-
stances and challenges that will require unanticipated
response efforts’.1 I, hereby, would like to make an additional
comment on disaster-related education for patients. What
should we teach patients? The education program for the
primary management of dialysis2 at home or nearby clinics
might be a possible useful topic for countries where machines
are easily available and the general populations are well
educated. However, for the poor countries, is this really
useful?
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Dr Wiwanitkit is concerned that, in the event of a disaster,
dialysis patients in poor countries may lack opportunities
to go to another location for dialysis, as well as resources to
manage dialysis in the home setting.1 These difficulties
highlight the more general point that poor patients are
likely to be especially vulnerable in a disaster, as Abdel-
Kader and Unruh2 have emphasized. For all patients,
possible disaster scenarios should be discussed, and there
should be a detailed disaster plan that is repeatedly
reviewed and practiced. Each patient should have a
‘survival kit’ that contains a list of the patient’s medications
and information about the specific treatment prescription,
information needed by medical relief workers. It is
especially important that patients receive information
about following strict fluid restriction and emergency diet
policy when the availability of dialysis treatments is limited
for a period of time.3 Sever et al.3 have also recommended
that patients store potassium exchange resins as a way to
prevent hyperkalemia when dialysis treatment cannot be
obtained in the initial days after a disaster.
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Targeting hyperphosphatemia:
truth or dare
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To the Editor: We are pleased that Isakova et al.1 have
generated the momentum for long-awaited randomized trials
on phosphorus management in patients with chronic kidney
disease. We fully agree that these are long overdue. Treatment
of millions of patients worldwide, following the Kidney
Disease Outcome Quality Initiative guidelines,2 is based
on experimental and observational data, rather than on
prospective trials. Predictably, but somewhat disappointingly,
Isakova et al. rebut the concept of a placebo-controlled
randomized controlled trial of phosphorus binders in
hemodialysis patients. They argue this would be considered
unethical, given the wide acceptance of current practice
guidelines for maintaining serum phosphate levels between
3.5 and 5.5 mg/dl.1 Would it not make more sense, when
designing these pivotal trials, to challenge these targets?
First, phosphate level targets refer to predialysis concen-
trations and do not take into account the sawtooth pattern of
phosphorus concentrations. The time-averaged phosphorus
exposure in hemodialysis patients is about 30% lower than
that suggested by predialysis phosphorus concentrations.
Second, although observational data unequivocally demon-
strate associations between high phosphorus and adverse
outcomes, numerous interventional studies in, for example,
diabetes or with erythropoietin therapy have shown that
‘normalization’ does not equal the optimal therapeutic
target.3,4 Third, availability of calcimimetics obviates the
need for phosphate binder therapy to control secondary
hyperparathyroidism. Finally, treat-to-target trials likely
require a combination of several phosphorus binders, thereby
introducing heterogeneity in treatment effects, and thus
jeopardizing the safety evaluation of individual phosphate
binders.5
When looking for the truth about phosphate control, we
might need to dare and ‘violate’ phosphorus targets in
randomized trials.
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